Applicability of the Streptozotocin-Induced Diabetes Model in Rats for the Detection of Lithium Salts Cytoprotective Effects - Abstract
Abstract
*Corresponding author
Rita Ostrovskaya, Research Zakusov Institute of
Pharmacology, Baltiiskaya 8, 125315, Russia, Tel:
+7-499-151-18-81; Fax: +7-499-151-12-61; Email: rita.
Submitted: 29 May 2017
Accepted: 27 June 2017
Published: 29 June 2017
Copyright
© 2017 Ostrovskaya et al.
OPEN ACCESS
Keywords
• Diabetes
• GSK-3?
• Streptozotocin
• Lithium salts
• Cytoprotection
Based on importance of kinase-3? glycogen synthase (GSK-3?) and ambiguity of data concerning the action of GSK-3? inhibitors on the development
of diabetes, it seems reasonable to continue the study of this issue. Considering the fact, that the decrease of ?-cells amount determines the dynamics of the
diabetes development and that streptozotocin (STZ) model reproduces the loss of ?-cells, the goal of this work was to evaluate the possible cytoprotective
effect of two lithium salts (chloride and carbonate) and to study their action on the functional manifestations of diabetes (hyperglycemia, polydipsia, weight
loss) on the STZ model of diabetes in experiments on rats. STZ (single dose of 40mg/kg i.p.) was shown to increase the glucose blood level up to 27mmol/l,
cause body weight decrease, polydipsia, MDA blood level increment and the loss of pancreatic ?-cells detected by immunohistochemical analysis. Lithium
chloride and lithium carbonate administrated for 28 days after STZ injection in doses of 10mg/kg and 8,9mg/kg correspondingly diminished the blood glucose
level up to 12mmol/l to the end of experiment. Both lithium salts attenuated the body weight decrease, polydipsia and polyphagia, MDA level augmentation
caused by STZ. The immunohistochemical examination shown that STZ diminished the amount of insulin-containing ?-cells approximately 4 times, while lithium
salts therapy results in two-fold increase of their amount comparing to untreated STZ group. The degree of pancreatic ?-cells protection correlates with the
level of anti-hyperglycemic activity.